Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.

Abstract: A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: When a short-circuit failure of any of switch portions (13) including switch elements (11) and parallel-connected feedback diodes (12) of an inverter circuit (7) is detected during the operation of a motor (1), a switch portion (13) where the short-circuit failure has occurred is checked for whether it is on the positive polarity side or the negative polarity side. The switch elements (11) are so controlled that all the switch portions (13) on the same polarity side as where the short-circuit has occurred are brought into a conducted state and all the others are disconnected. This prevents a large electric current from flowing into each switch portion of the inverter circuit without requiring any switch to block the power distribution between a motor and the inverter circuit when a short-circuit failure of the switch portion of the inverter circuit occurs.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Abstract: A particulate collection system, including a particulate matter analyzer and collecting filter, provides a method of analyzing and collecting samples from fluids, such as collecting particulate matter from air. A mass measuring unit and composition analyzing unit can be provided for either simultaneous or immediately consecutive measurements within a single instrument. The filter material can have an antistatic electricity characteristic and can be impregnated with reference material to enable calibration of the composition analyzing unit.

Abstract: The present invention relates to a catalyst for reducing mercury, which comprises a reagent comprising any of the sulfites of potassium, sodium, calcium and magnesium, or any of the phosphates thereof, or a combination of them, as a main reagent of a catalyst component. And the present invention relates to the catalyst for reducing mercury, wherein the catalyst component is mixed with a different salt as an agent for inhibiting crystallization of the catalyst component.

Abstract: The present invention relates to a catalyst for reducing mercury, which comprises a reagent comprising any of the sulfites of potassium, sodium, calcium and magnesium, or any of the phosphates thereof, or a combination of them, as a main reagent of a catalyst component. And the present invention relates to the catalyst for reducing mercury, wherein the catalyst component is mixed with a different salt as an agent for inhibiting crystallization of the catalyst component.

Abstract: A heat exchanger includes left and right header tanks disposed in parallel; top and bottom side plates that couple respectively both ends of the pair of the header tanks; a first plurality of tubes connected between the pair of the header tanks at both ends that are disposed in a region nearer the bottom side plate as a condenser; and a second plurality of tubes that are disposed in a region nearer the top side plate as an oil cooler. Each tube in the second tubes has a cross-sectional shape identical to that of each tube in the first tubes and the top side plate is formed to have a squared U-shaped cross section so that a return pipe communicating with the second tubes can be disposed along a groove having the squared U-shaped cross section of the top side plate.

Abstract: A specifying portion 371 for specifying a favorite content list of other user “U” indicating same contents as those indicated by a favorite content list D_t1 of a user U_A among a plurality of favorite content lists D_t respectively indicating contents favored by respective users “U” defined by corresponding to the respective users “U”; and a recommendation list generation portion 372 for ranking based on number of respective contents indicated by the favorite content lists D_t of other users by using the favorite content list D_t1 and a favorite content lists of other users “U”, and generating a recommendation content list D_r1; are provided.

Abstract: When a short-circuit failure of any of switch portions (13) including switch elements (11) and parallel-connected feedback diodes (12) of an inverter circuit (7) is detected during the operation of a motor (1), a switch portion (13) where the short-circuit failure has occurred is checked for whether it is on the positive polarity side or the negative polarity side. The switch elements (11) are so controlled that all the switch portions (13) on the same polarity side as where the short-circuit has occurred are brought into a conducted state and all the others disconnected. This prevents a large electric current from flowing into each switch portion of the inverter circuit without requiring any switch to block the power distribution between a motor and the inverter circuit when a short-circuit failure of the switch portion of the inverter circuit occurs.

Abstract: When a signal path in a signal outputting device is changed, the signal outputting device indicates signal path change information representing the change in the signal path to a signal inputting device. Based on the signal path change information, the signal inputting device adaptively changes a signal path between the signal outputting device and the signal inputting device. The signal inputting device can know the signal path in the signal outputting device easier than heretofore, and can simply change the signal path between the signal outputting device and the signal inputting device.

Abstract: A certification result obtained by a master device 2 for a slave device 3 is notified to a master data processing device 6 while making a part of determination result data supplied from a master certification device 5 to the master data processing device 6 accompany with the rest of the determination result data supplied from the master certification device 5 to the master data processing device 6 through the slave device 3. Even when the part of the determination result data and the rest of the determination result data are plain text, they are given from different routes 11 and 10. Accordingly, the confidentiality for the determination result can be enhanced as compared to the case where all of the determination results are given from the master certification device 5 to the master data processing device 6.